CRSP News and Press, CRISPR Therapeutics AG From 12/11/23

2023-12-11 12:41:31 ET On Monday, for the third straight day, shares of CRISPR Therapeutics (NASDAQ: CRSP) stock declined, falling 11.2% through 11:30 a.m. ET -- which is kind of crazy when you think about it. Just three days ago, CRISPR announced that the U.S. Food and Drug...

2023-12-11 12:11:06 ET More on CRISPR Therapeutics Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) FDA approves...

2023-12-11 06:44:02 ET Summary The S&P 500 reached 4,600 for the first time since March 2022. The current bull plateau is strong enough to avoid a recession but sluggish enough for the plateau to last for at least 3 years. Cash cows on the bull plateau are helping instant ...

2023-12-11 05:43:00 ET Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with sickle cell disease. The medical community cheered, but the ...

2023-12-10 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: The Week Ahead

2023-12-08 20:06:38 ET Summary The FDA has granted approval to a CRISPR-based gene editing therapy for the first time in history, validating the approach. The therapy, called Casgevy, is approved to treat Sickle Cell Disease after showing positive results in clinical trials, funct...

– First-ever approval of a CRISPR-based gene-editing therapy in the U.S. – – Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment – – Multiple auth...

2023-12-08 11:47:10 ET The Crispr Therapeutics (NASDAQ: CRSP) stock price moved sideways after the Food and Drug Administration (FDA) approved Casgevy. The shares were trading at $70.30 on Friday, where they have been in the past few days. They are 84% above their lowest level in Novemb...

2023-12-08 11:42:02 ET More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc. CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Vertex Pharmaceuticals Looks Expensive, Though It Isn't Biotechs p...

2023-12-08 11:39:48 ET More on bluebird bio bluebird bio Isn't Priced For Success Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment bluebird bio, Inc. (BLUE) Q3 2023 Earnings Call Transcript Morgan Stanley ups bluebird to equal weight...